Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen in Post-COVID Fatigue
NCT05592418Phase 2Completed
- Sponsor
- AIM ImmunoTech
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Ampligen with Placebo (2 arms). Primary endpoint: Change From Baseline in PROMIS Fatigue Score (T-Score) at Week 13. Started Jun 2023; status: completed.
02
Drugs
rintatolimod
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05592418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592418.